As Covid program advances, Enanta’s new CMO says it’s not ‘limited to antivirals’; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can expand its horizons while also figuring out a way to address the yearslong Covid pandemic with an expected Phase II launch later this year.

“I…